Apellis Pharmaceuticals Inc (NASDAQ:APLS) Insider Trading Activity – COO Sold 42,460 shares of Stock

ME Staff

5 years ago

Insider Trading Activity For Apellis Pharmaceuticals Inc (NASDAQ:APLS)

Pascal Deschatelets , COO of Apellis Pharmaceuticals Inc (NASDAQ:APLS) reportedly Sold 42,460 shares of the company’s stock at an average price of 24.82 for a total transaction amount of $1,053,857.20 SEC Form

Insider Trading History For Apellis Pharmaceuticals Inc (NASDAQ:APLS)

On 11/13/2017 Global Strategic Fund I Venbio, Major Shareholder, bought 127,515 with an average share price of $14.00 per share and the total transaction amounting to $1,785,210.00.

On 5/24/2018 Lukas Scheibler, Insider, bought 2,935 with an average share price of $20.37 per share and the total transaction amounting to $59,785.95.

On 9/14/2018 David O Watson, General Counsel, sold 15,776 with an average share price of $18.78 per share and the total transaction amounting to $296,273.28.

On 9/19/2018 Morningside Venture Investment, Major Shareholder, bought 140,000 with an average share price of $18.34 per share and the total transaction amounting to $2,567,600.00.

On 9/21/2018 Morningside Venture Investment, Major Shareholder, bought 81,323 with an average share price of $19.48 per share and the total transaction amounting to $1,584,172.04.

On 3/11/2019 Morningside Venture Investment, Major Shareholder, bought 441,176 with an average share price of $17.00 per share and the total transaction amounting to $7,499,992.00.

On 8/15/2019 Cedric Francois, CEO, sold 10,000 with an average share price of $26.80 per share and the total transaction amounting to $268,000.00.

Analyst Ratings History For Apellis Pharmaceuticals Inc (NASDAQ:APLS)

On 12/4/2017 Evercore ISI Initiated Coverage of rating Outperform
On 12/6/2018 Citigroup Boost Price Target of rating Buy with a price target of $34.00 to $40.00
On 1/8/2019 B. Riley Initiated Coverage of rating Buy with a price target of $40.00
On 3/28/2019 Robert W. Baird Initiated Coverage of rating Outperform to Outperform with a price target of $45.00
On 7/9/2019 Oppenheimer Initiated Coverage of rating Outperform with a price target of $52.00 to $52.00
On 7/12/2019 JPMorgan Chase & Co. Upgraded rating Neutral to Overweight with a price target of $35.00 to $49.00
On 7/31/2019 Cowen Set Price Target of rating Buy with a price target of $40.00

Recent Trading Activity for Apellis Pharmaceuticals Inc (NASDAQ:APLS)
Shares of Apellis Pharmaceuticals Inc closed the previous trading session at with 405900 shares trading hands.